|
FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL
|
30 June 2023 at 8:40am
|
|
Change of Director's Interest Notice
|
28 June 2023 at 5:15pm
|
|
PYC Investor Update Presentation
|
16 June 2023 at 8:55am
|
|
Q2 Investor Call 16 June 2023
|
8 June 2023 at 8:50am
|
|
Phelan-McDermid Syndrome & CNS platform presentation
|
6 June 2023 at 9:50am
|
|
Notice of General Meeting/Proxy Form
|
2 June 2023 at 4:55pm
|
|
Appointment of Joint Company Secretary
|
1 June 2023 at 5:05pm
|
|
Ceasing to be a substantial holder
|
22 May 2023 at 6:20pm
|
|
Ceasing to be a substantial holder
|
22 May 2023 at 6:15pm
|
|
Cleansing Notice Under Section 708AA
|
19 May 2023 at 10:10am
|
|
Application for quotation of securities - PYC
|
19 May 2023 at 10:05am
|
|
Proposed issue of securities - PYC
|
11 May 2023 at 10:30am
|
|
Placement Supporting Document
|
11 May 2023 at 10:30am
|
|
Successful Completion of $30m Placement
|
11 May 2023 at 10:30am
|
|
Trading Halt
|
9 May 2023 at 9:45am
|
|
PYC Presenting at TIDES USA 2023
|
2 May 2023 at 9:20am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 9:35am
|
|
Commencement of First Clinical Study in RP11
|
26 April 2023 at 9:20am
|
|
PYC BIO 2023 Presentation
|
19 April 2023 at 9:40am
|
|
Second Drug Program Progressing to Human Trials
|
3 April 2023 at 10:15am
|
|
Cleansing Notice Under Section 708AA
|
7 March 2023 at 8:15pm
|
|
Application for quotation of securities - PYC
|
7 March 2023 at 8:10pm
|
|
FDA Clears PYC to Commence First Human Trials in RP11
|
6 March 2023 at 9:45am
|
|
Trading Halt
|
2 March 2023 at 8:20pm
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 6:10pm
|
|
PYC Investor Update Presentation
|
17 February 2023 at 8:35am
|
|
Issue of Options
|
15 February 2023 at 5:55pm
|
|
Notification regarding unquoted securities - PYC
|
15 February 2023 at 5:55pm
|
|
Q1 Investor Call 17 February 2023
|
10 February 2023 at 8:50am
|
|
PYC Corporate Presentation - February 2023
|
3 February 2023 at 11:30am
|
|
VP-001 IND Lodgement
|
2 February 2023 at 9:35am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
20 January 2023 at 8:45am
|
|
Notification of cessation of securities - PYC
|
21 December 2022 at 7:00pm
|
|
PYC Increases Ownership of VP-001 Program
|
29 November 2022 at 8:45am
|
|
Results of Annual General Meeting
|
23 November 2022 at 4:20pm
|
|
2022 AGM Chairman's Address and CEO Presentation
|
23 November 2022 at 12:55pm
|
|
Annual General Meeting - Conference Call
|
21 November 2022 at 12:55pm
|
|
Successful Toxicology Studies Pave Way for Human Trials
|
7 November 2022 at 8:45am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 8:30am
|
|
Issue of Options
|
28 October 2022 at 7:35pm
|
|
Notification regarding unquoted securities - PYC
|
28 October 2022 at 7:35pm
|
|
Notice of Annual General Meeting/Proxy Form
|
14 October 2022 at 6:55pm
|
|
PYC Presenting on Drug Delivery Platform at OTS 2022 Meeting
|
3 October 2022 at 1:20pm
|
|
Central Nervous System Drug Program Added to PYC Pipeline
|
27 September 2022 at 8:55am
|
|
Corporate Governance Statement and Appendix 4G
|
23 September 2022 at 9:25am
|
|
Annual Report to shareholders
|
23 September 2022 at 9:25am
|
|
Preliminary Final Report
|
31 August 2022 at 9:20am
|
|
PYC Shareholder Update
|
18 August 2022 at 9:55am
|
|
Change of Director's Interest Notice
|
11 August 2022 at 12:20pm
|
|
PYC Therapeutics Investor Call - 18 August 2022
|
9 August 2022 at 10:30am
|
